Combined therapy of patients with recurrent cystitis using a complex of natural antimicrobial peptides and cytokines: first results

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Urinary tract infections (UTIs) remain an important problem in urology due to their high prevalence and tendency to relapse. The improvement of the treatment outcomes in chronic cystitis is still relevant. Material and methods. A total of 91 patients were included in prospective, multicenter, randomized, comparative, controlled study. They were randomized into three groups: in the comparison group 1 (n=32) basic therapy was administered for 5 days. In the comparison group 2 (n=28) basic therapy was combined with rectal suppositories Superlymph® 25 IU once a day for 10 days. In the main group (n=31) basic therapy in combination with rectal suppositories Superlymph® 10 IU once a day for 20 days were prescribed. The basic therapy included a combination of two antimicrobial drugs: fosfomycin trometamol 3.0 g at night once on the first day of therapy, and furazidin 100 mg three times a day after meals for 5 days. Pathogenetic treatment was not prescribed in comparison group 1, but administered for 10 days and 20 days in comparison group 2 and main group, respectively. Results. After the completion of etiotropic therapy, a significant effect in all groups was shown. At the same time, at the 2nd visit, there was a significantly better results in patients who received Superlymph® rectal suppositories, both at a dose of 10 U and at a dose of 25 U, without any differences between two schemes. The frequency and severity of cystitis symptoms at the end of etiopathogenetic therapy in the main group was less pronounced than in the comparison groups (p=0.0001), and a significant difference was found between comparison groups 1 and 2 (p=0.0001). The use of Superlymph® significantly improved the parameters of microcirculation in the urethra, however, there was no difference between comparison group 2 and main group. Conclusion. Etiopathogenetic therapy, including Superlymph® rectal suppositories at a dose of 10 IU and 25 IU in patients with chronic cystitis, can significantly improve the results of combination therapy. Analysis of the symptoms score of acute cystitis showed the superiority of longer-term use of Superlymph® rectal suppositories at a reduced dosage (10 units). Peptide-cytokine therapy led to a significant improvement in local microcirculation in comparison group 2 and the main group.

Full Text

Restricted Access

About the authors

E. V Kulchavenya

FGBOU VO Novosibirsk State Medical University of Ministry of Health of Russia; Medical Center “Avicenna”; Research Institute of Ministry of Health of Russia

Email: urotub@yandex.ru
Ph.D., MD, professor, Chief Researcher at TB; Head of the Urologic Department, professor at Department of Tuberculosis Novosibirsk, Russia; Novosibirsk, Russia

A. I Neymark

FGBOU VO Altai State Medical University of the Ministry of Health of Russia

Ph.D., MD, professor, Head of the Department of Urology and Andrology with a course of Specialized Surgery Barnaul, Russia

A. Yu Tcukanov

FGBOU VO Omsk State Medical University of the Ministry of Health of Russian Federation

Ph.D., MD, professor, Head of the Department of Surgical Diseases and Urology Omsk, Russia

P. S Plugin

FGBOU VO Novosibirsk State Medical University of Ministry of Health of Russia

Ph.D. student at the Department of Urology Novosibirsk, Russia

A. B Neymark

FGBOU VO Altai State Medical University of the Ministry of Health of Russia

student Barnaul, Russia

M. V Razdorskaya

NUZ KB “RJD-Medicine”

urologist at the Department of Urology Barnaul, Russia

References

  1. Гаджиева З.К., Казилов Ю.Б. Особенности подхода к профилактике рецидивирующей инфекции нижних мочевыводящих путей. Урология. 2016;(3):65-76.
  2. Кузьмин И.В., Аль-Шукри С.Х., Слесаревская М.Н. Лечение и профилактика рецидивирующей инфекции нижних мочевых путей у женщин. Урологические ведомости. 2019;9(2):5-10.
  3. Kulchavenya E. The best rules for antimicrobial stewardship in urogenital tract infections. Curr Opin Urol. 2020 Nov;30(6):838-844. doi: 10.1097/MOU.0000000000000817.
  4. Giannarini G., Klatte T., Catto J.W., Briganti A. Beware of Bugs! Hot Issues in Urinary Tract Infections and Inflammation. Eur Urol Focus. 2016 Oct;2(4):339-340. doi: 10.1016/j.euf.2016.08.014.
  5. Bader M.S., Loeb M., Leto D., Brooks A.A. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Postgrad Med. 2020 Apr; 132(3) :234-250. doi: 10.1080/00325481.2019.1680052.
  6. Сабадаш М.Е., Шуляк А.В. Канефрон® н при лечении рецидивирующего цистита у женщин детородного возраста: рандомизированное контролируемое исследование. Семейная медицина. 2020. № 3 (89). С. 24-28).
  7. Слесаревская М.Н., Кузьмин И.В., Краева Л.А., Смирнова Е.В. Эффективность комбинированной биологически активной добавки Уронекст у женщин с рецидивирующими циститами: клинико-микробиологическое исследование. Экспериментальная и клиническая урология 2022; 15(2) 120-128; https://doi.org/10.29188/2222-8543-2022-15-2-120-128
  8. Кульчавеня Е.В. Бреусов А.А., Брижатюк Е.В., Шевченко С.Ю. Острый цистит - всегда ли нужен антибиотик? Урология. 2016;1:25-28.
  9. Хрянин А.А., Решетников О.В. Комбинированная терапия хронического бактериального простатита. Урология.2016;3 (supplement):91-96).
  10. Dhillon S. Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections. Drugs. 2018 Aug;78(12):1259-1270. doi: 10.1007/s40265-018-0966-7. Erratum in: Drugs. 2018 Sep;78(13):1383.
  11. Тиктинский О.Л. Воспалительные неспецифические заболевания мочеполовых органов. 1984, изд-во: Медицина, Л., 304 с.
  12. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment. https://www.who.int/publications/i/item/9789240007048 (access 20/10/22).
  13. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment. https://www.who.int/publications/i/item/9789240048126 (access 20/10/22)
  14. Васильева И.А., Баласанянц Г.С., Борисов С.Е., Бурмистрова И.А., Валиев Р.Ш., Кульчавеня Е.В. и др. Туберкулез у взрослых. Федеральные клинические рекомендации М., 2022.
  15. Bin Hafeez A., Jiang X., Bergen P.J., Zhu Y. Antimicrobial Peptides: An Update on Classifications and Databases.Int J Mol Sci. 2021 Oct 28;22(21):11691. doi: 10.3390/ijms222111691.
  16. Fry D.E. Antimicrobial Peptides. Surg Infect (Larchmt). 2018 Nov/ Dec;19(8):804-811. doi: 10.1089/sur.2018.194.
  17. Boparai J.K., Sharma P.K. Mini Review on Antimicrobial Peptides, Sources, Mechanism and Recent Applications. Protein Pept Lett. 2020;27(1):4-16. doi: 10.2174/0929866526666190822165812.
  18. Mwangi J., Hao X., Lai R., Zhang Z.Y. Antimicrobial peptides: new hope in the war against multidrug resistance. Zool Res. 2019 Nov 18;40(6):488-505. doi: 10.24272/j.issn.2095-8137.2019.062.
  19. Xia X., Cheng L., Zhang S,. Wang L., Hu J. The role of natural antimicrobial peptides during infection and chronic inflammation. Antonie Van Leeuwenhoek. 2018 Jan;111(1):5-26. doi: 10.1007/s10482-017-0929-0.
  20. Mahlapuu M., Björn C., Ekblom J. Antimicrobial peptides as therapeutic agents: opportunities and challenges, Critical Reviews in Biotechnolo gy.2020;40(7):978-992. doi: 10.1080/07388551.2020.1796576
  21. van Hoek M.L. Antimicrobial peptides in reptiles. Pharmaceuticals. 2014;7:723-753. doi: 10.3390/ph7060723.
  22. Nawrot R., Barylski J., Nowicki G., Broniarczyk J., Buchwald W., Gozdzicka-Jozefiak A. Plant antimicrobial peptides. Folia Microbiol. 2014;59:181-196. doi: 10.1007/s12223-013-0280-4.
  23. Chung P.Y., Khanum R. Antimicrobial peptides as potential anti-biofilm agents against multidrug-resistant bacteria. J. Microbiol. Immunol. Infect. 2017;50:405-410. doi: 10.1016/j.jmii.2016.12.005.
  24. Radek K., Gallo R. Antimicrobial peptides: Natural effectors of the innate immune system. Semin. Immunopathol. 2007;29:27-43. doi: 10.1007/s00281-007-0064-5.
  25. Hancock R.E., Sahl H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 2006;24:1551- 1557. doi: 10.1038/nbt1267.
  26. Lazzaro B.P., Zasloff M., Rolff J. Antimicrobial peptides: Application informed by evolution. Science. 2020;368:eaau5480. Doi: 10.1126/ science.aau5480.
  27. Diamond G., Beckloff N., Weinberg A., Kisich K.O. The roles ofantimicrobial peptides in innate host defense. Curr. Pharm. Des. 2009;15:2377-2392. doi: 10.2174/138161209788682325.
  28. Magana M., Pushpanathan M., Santos A. L., Leanse L., Fernandez M., Ioannidis A., Giulianotti M.A., Apidianakis Y., Bradfute S., Ferguson A.L., Cherkasov A., Seleem M.N., Pinilla C, de la Fuente-Nunez C., Lazaridis T., Dai T., Houghten R.A., Hancock R.E.W., Tegos G.P. The value of antimicrobial peptides in the age of resistance. Lancet Infect Dis. 2020 Sep;20(9):e216-e230. doi: 10.1016/S1473-3099(20)30327-3.
  29. Lau J.L., Dunn M.K. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg. Med. Chem. 2018;26(10):2700-2707. http://dx.doi.org/10.1016/j.bmc.2017.06.052.
  30. Bonkat G (chair), Bruyere F., Cai T., Geerlings S.E., Koves B., Schubert S., Wagenlehner F. EAU Guidelines Edn. presented at the EAU Annual Congress Milan Italy 2021. ISBN 978-94-92671-13-4. 2021
  31. Цистит у женщин. Клинические рекомендации. Доступ: https://www.ooorou.ru/upload/iblock/0cf/_-_-_.pdf).
  32. Набока Ю.Л., Гудима И.А., Коган М.И., Ибишев Х.С., Черницкая М.Л. Микробный спектр мочи и биоптатов мочевого пузыря у женщин с хроническим рецидивирующим циститом. Урология. 2013;4:16-18
  33. Кульчавеня Е.В., Шевченко С.Ю., Чередниченко А.Г. Диагностика и лечение цистита: вопросов больше, чем ответов? Урология. 2016;(5):37-42.
  34. Ибишев Х.С., Лаптева Т.О., Крахоткин Д.В., Рябенченко Н.Н. Роль папилломавирусной инфекции в развитии рецидивирующей инфекции нижних мочевых путей. Урология. 2019;5:134-137.
  35. Hutchings M.I., Truman A.W., Wilkinson B. Antibiotics: Past, present and future. Curr. Opin. Microbiol. 2019;51:72-80. doi: 10.1016/j.mib.2019.10.008.
  36. Luo Y, Song Y. Mechanism of Antimicrobial Peptides: Antimicrobial, Anti-Inflammatory and Antibiofilm Activities.Int J Mol Sci. 2021 Oct 22;22(21):11401. doi: 10.3390/ijms222111401.
  37. Barea B.M., Veeratterapillay R, Harding C. Nonantibiotic treatments for urinary cystitis: an update. Curr Opin Urol. 2020 Nov;30(6):845-852. doi: 10.1097/MOU.0000000000000821.
  38. Джалилова А.Н., Царуева Т.В., Джалилова Д.Н., Какваева С.Ш., Мехтиханова З.А., Кабартиева Ю.А. Хронический рецидивирующий цистит у женщин репродуктивного возраста: современные тренды диагностики и лечения. Уральский медицинский журнал. 2020;1(184):76-7
  39. Аполихина И.А., Саидова А.С., Тетерина Т.А. Эффективность применения локальной цитокинотерапии в комплексном лечении пациенток с хроническим циститом. Акушерство и гинекология. 2019; 12: https://dx.doi.org/10.18565/aig.2019.12.
  40. Russian Саидова А.С., Аполихина И.А., Ганковская Л.В. и соавторы. Эффективность применения цитокинотерапии в комплексном лечении пациенток с хроническим рецидивирующим циститом. Медицинский оппонент/ 2021; (14):59-69.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies